Back to top
Logo
Print |

Table of contents

"Progressions 2007: The Ernst & Young Global Pharmaceutical Report" focuses on how pharmaceutical companies are managing the risks associated with product safety even as they manage financial and operational performance.

Browse the contents below to see the full scope of this report. You can also download and read three articles, or request the full report.


    Introduction

    • To our clients and friends
      Christopher Gray, Ernst & Young, Managing Editor, "Progressions"
    • Returns on safety investments
      Carolyn Buck Luce, Ernst & Young, Global Pharmaceutical Sector Leader

    Articles

    • Protecting product integrity: an integrated approach
      Jerry Wald, Ernst & Young, Carol Landsman, Ernst & Young
    • Planning for Surprises
      Mark Campbell, Ernst & Young, Tracee Fultz, Ernst & Young
    • Accounting for safety: an Ernst & Young roundtable
      Moderator: Howard Brooks, Ernst & Young
      Ernst & Young Panel Participants: Scott Bruns, Jim Bulkowski, Les Clifford, Anthony Masherelli, Kathleen Smith, Bruce Stump
    • Contracting research: criteria to live by
      Karoline Dubiel, Ernst & Young, Jeffrey Steinberg, Ernst & Young
    • On the safe side of deals
      Jeffrey Greene, Ernst & Young
    • Drug safety in Europe: a model for the United States?
      Linda Horton, Hogan & Hartson LLP, Gary Uy, Hogan & Hartson LLP
    • Europe’s risk management plans — beyond pharmacovigilance
      Virginie Lefebvre-Dutilleul, Ernst & Young, Frank Kumli, Ernst & Young
    • A new era in drug safety regulation
      Michael McCaughan, Senior Editor, The RPM Report
    • Product safety compliance: a widening view
      Tom Gregory, Ernst & Young
    • Data analytics: the future of patient safety and operational excellence
      Tom Madden, Ernst & Young, Roshan Ramlukan, Ernst & Young
    • Treating corruption
      Ted Acosta, Ernst & Young
    • Medical affairs professionals: balancing the benefits and risks
      Eileen Erdos, Ernst & Young
    • India: Seeking a safe and innovative pharmaceutical market
      Mamidanna Venkateswarlu, Drugs Controller General of India, Ministry of Health and Family Welfare
    • Leveraging customs
      Colm Halpin, Ernst & Young
    • Preparing for a drug recall
      John Smart, Ernst & Young, Melissa Whitman, Ernst & Young
    • Managing electronic data: litigation readiness for drug recalls
      Bhavna Sethi, Ernst & Young

Global Pharmaceutical Center
Request your copy today

To request your own copy of "Progressions 2007", contact your local pharmaceutical representative.

Podcasts from the Global Pharmaceutical Center

What choices can today’s pharma companies make to balance risks and rewards, avoid major pitfalls, and grow their businesses globally? Global Pharmaceutical Center leaders address these questions in our podcast series "Capturing the global advantage". Visit our US site to subscribe.
Ernst & Young refers to one or more of the member firms of Ernst & Young Global Limited (EYG), a UK private company limited by guarantee. EYG is the principal governance entity of the global Ernst & Young organization and does not provide any service to clients. Services are provided by EYG member firms. Each of EYG and its member firms is a separate legal entity and has no liability for another such entity's acts or omissions. Certain content on this site may have been prepared by one or more EYG member firms.